ARTICLE | Tools & Techniques
Locus co-founders open door to new CRISPR systems
A different type of CRISPR system that works in human cells creates new therapeutic opportunities
October 7, 2019 1:49 AM UTC
As most gene editing companies remain laser-focused on the well-studied CRISPR-Cas9 system marred in IP disputes, a new study from Locus co-founders shows that an entirely different type of CRISPR system can tune gene expression in eukaryotic cells.
The discovery opens the field to a potentially huge collection of new CRISPR systems, some of which could have technical benefits and all of which should have a less complicated patent landscape than their more established Cas9 counterpart. ...
BCIQ Target Profiles